ArticleAnnals of African medicine2026
A Case series of Acute Methotrexate Toxicity.
Article in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAcute methotrexate toxicity represents a serious medical emergency with significant morbidity and mortality. This case series aims to characterize clinical presentations, risk factors, and outcomes of patients with acute methotrexate toxicity admitted to a tertiary care hospital. We retrospectively analyzed six patients who presented with acute methotrexate toxicity. Clinical presentations, laboratory parameters, management strategies, and outcomes were evaluated. All patients received leucovorin rescue therapy and supportive care. The cohort comprised six patients (median age 63 years, range 54-96 years) with 67% female predominance. All patients presented with mucocutaneous manifestations, predominantly oral ulcers (100%). Pancytopenia was observed in all cases with available complete blood counts. Dosing errors were the primary etiology in 67% of cases, with patients erroneously taking weekly doses daily. Additional risk factors included advanced age and chronic kidney disease. Laboratory findings revealed severe neutropenia (median total leukocyte count range 480-5300 cells/mm 3 ), with progressive hematological deterioration requiring intensive monitoring. Treatment consisted of immediate methotrexate discontinuation, leucovorin rescue therapy (15 mg IV), granulocyte colony-stimulating factor in severe cases, and supportive care. Five patients (83%) recovered completely within 5-14 days, while one elderly patient with chronic kidney disease died from complications, yielding a 17% mortality rate. Acute methotrexate toxicity results primarily from dosing errors. Mucocutaneous ulcers serve as early warning signs of systemic toxicity. Early recognition, prompt leucovorin rescue therapy, and aggressive supportive care are crucial for favorable outcomes. Enhanced patient education and monitoring protocols are essential for prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.